These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21477796)

  • 41. Prevention and treatment of papillomavirus-related cancers through immunization.
    Frazer IH; Leggatt GR; Mattarollo SR
    Annu Rev Immunol; 2011; 29():111-38. PubMed ID: 21166538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in human papilloma virus vaccines: a patent review.
    Cho HJ; Oh YK; Kim YB
    Expert Opin Ther Pat; 2011 Mar; 21(3):295-309. PubMed ID: 21250872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccines and immunization against human papillomavirus.
    Christensen ND; Budgeon LR
    Curr Probl Dermatol; 2014; 45():252-64. PubMed ID: 24643192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Anti human-papillomavirus vaccines: concepts, aims and trials].
    Bourgault-Villada I
    Rev Med Interne; 2007 Jan; 28(1):22-7. PubMed ID: 17070619
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New adjuvants in evolving vaccine strategies.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Opin Biol Ther; 2011 Jul; 11(7):827-32. PubMed ID: 21609186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
    Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum.
    Yu Y; Guo J; Li D; Liu Y; Yu Y; Wang L
    Vaccine; 2018 Aug; 36(32 Pt B):4927-4934. PubMed ID: 30037483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determination of freeze damage on HPV vaccines by use of flow cytometry.
    Østergaard E; Frandsen PL; Sandberg E
    Biologicals; 2015 Jul; 43(4):266-73. PubMed ID: 25921611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meeting report VLPNPV: Session 3: Immune responses.
    Morrison TG
    Hum Vaccin Immunother; 2014; 10(10):3064-7. PubMed ID: 25529229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Raising expectations for subunit vaccine.
    Schiller JT; Lowy DR
    J Infect Dis; 2015 May; 211(9):1373-5. PubMed ID: 25420478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Development of a second generation prophylactic vaccine against human papillomavirus].
    Leonardo A; Cerutti ML; Risso M; González M; Camporeale G; de Prat Gay G
    Medicina (B Aires); 2011; 71(3):261-6. PubMed ID: 21745779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.
    Saboo S; Tumban E; Peabody J; Wafula D; Peabody DS; Chackerian B; Muttil P
    Mol Pharm; 2016 May; 13(5):1646-55. PubMed ID: 27019231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.
    Frietze KM; Lijek R; Chackerian B
    Expert Rev Vaccines; 2018 Nov; 17(11):959-966. PubMed ID: 30300019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Major findings and recent advances in virus-like particle (VLP)-based vaccines.
    Mohsen MO; Zha L; Cabral-Miranda G; Bachmann MF
    Semin Immunol; 2017 Dec; 34():123-132. PubMed ID: 28887001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Quantitative analysis of nine types of virus-like particles in human papilloma virus bulk by size-exclusion chromatography].
    Long Z; Li X; Li X; Liu J; Nie J; Li C; Li Y; Huang T; Huang W
    Se Pu; 2021 Apr; 39(4):424-429. PubMed ID: 34227763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.
    Monie A; Hung CF; Roden R; Wu TC
    Biologics; 2008 Mar; 2(1):97-105. PubMed ID: 19707432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas.
    Govan VA; Rybicki EP; Williamson AL
    Virol J; 2008 Mar; 5():45. PubMed ID: 18355406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus.
    Pennisi M; Russo G; Ravalli S; Pappalardo F
    BMC Bioinformatics; 2017 Dec; 18(Suppl 16):544. PubMed ID: 29297294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine.
    Janitzek CM; Peabody J; Thrane S; H R Carlsen P; G Theander T; Salanti A; Chackerian B; A Nielsen M; Sander AF
    Sci Rep; 2019 Mar; 9(1):5260. PubMed ID: 30918267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A time-resolved fluorescence immunoassay for rapid and precise automatic quality control of human papillomavirus type 68 VLPs in human papillomavirus vaccine.
    Li Z; Wu M; Chen Y; Li Y; Zhang Z; Zhai X; Cao Y; Li X; Yang Y; Wu Y; Lin G
    J Immunol Methods; 2023 Aug; 519():113518. PubMed ID: 37385433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.